JPH0471894B2 - - Google Patents
Info
- Publication number
- JPH0471894B2 JPH0471894B2 JP61049384A JP4938486A JPH0471894B2 JP H0471894 B2 JPH0471894 B2 JP H0471894B2 JP 61049384 A JP61049384 A JP 61049384A JP 4938486 A JP4938486 A JP 4938486A JP H0471894 B2 JPH0471894 B2 JP H0471894B2
- Authority
- JP
- Japan
- Prior art keywords
- placenta
- cells
- effect
- cell
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000002826 placenta Anatomy 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000019522 cellular metabolic process Effects 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 30
- 238000000034 method Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- 239000000284 extract Substances 0.000 description 23
- 239000000126 substance Substances 0.000 description 21
- 230000004663 cell proliferation Effects 0.000 description 17
- 238000000605 extraction Methods 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 14
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 229920005654 Sephadex Polymers 0.000 description 10
- 239000012507 Sephadex™ Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000002523 gelfiltration Methods 0.000 description 9
- 239000013076 target substance Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 208000034423 Delivery Diseases 0.000 description 3
- 235000019780 Liver Tonic Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000000876 liver tonic Substances 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010038061 Chymotrypsinogen Proteins 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 anionic ion Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2278710A JPH03141299A (ja) | 1986-03-05 | 1990-10-16 | 牛胎盤抽出細胞代謝活性化物質 |
| JP2278711A JPH03148226A (ja) | 1986-03-05 | 1990-10-16 | 動物臓器由来蛋白質のウィルス不活化法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15971385 | 1985-07-18 | ||
| JP60-159713 | 1985-07-18 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2278711A Division JPH03148226A (ja) | 1986-03-05 | 1990-10-16 | 動物臓器由来蛋白質のウィルス不活化法 |
| JP2278710A Division JPH03141299A (ja) | 1986-03-05 | 1990-10-16 | 牛胎盤抽出細胞代謝活性化物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62116519A JPS62116519A (ja) | 1987-05-28 |
| JPH0471894B2 true JPH0471894B2 (no) | 1992-11-16 |
Family
ID=15699658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61049384A Granted JPS62116519A (ja) | 1985-07-18 | 1986-03-05 | 人胎盤抽出細胞代謝活性化物質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62116519A (no) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03148226A (ja) * | 1986-03-05 | 1991-06-25 | Ichimaru Pharcos Co Ltd | 動物臓器由来蛋白質のウィルス不活化法 |
| EP0302459A3 (en) * | 1987-08-04 | 1990-02-07 | Sumitomo Pharmaceuticals Company, Limited | Human placenta-derived thermostable cell growth factor and a process for production thereof |
| JPH0311007A (ja) * | 1989-06-06 | 1991-01-18 | Mikimoto Seiyaku Kk | 化粧品原料の製造方法 |
| IT1318405B1 (it) * | 2000-03-17 | 2003-08-25 | Piermario Biava | Composizione antitumorale costituita da una frazione di utero gravidoo di placenta di mammiferi. |
| CN107698675A (zh) * | 2017-07-12 | 2018-02-16 | 武汉博百欧生物科技有限公司 | 分离并纯化钙卫蛋白的方法及试剂盒 |
| CN109575103A (zh) * | 2018-12-06 | 2019-04-05 | 刘力伟 | 一种分离提取胎盘或脐带组织中水溶性蛋白分子的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260519A (ja) * | 1984-05-21 | 1985-12-23 | ベーリングヴエルケ・アクチエンゲゼルシヤフト | 組織蛋白ｐｐ↓１↓８、その取得方法およびその用途 |
-
1986
- 1986-03-05 JP JP61049384A patent/JPS62116519A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260519A (ja) * | 1984-05-21 | 1985-12-23 | ベーリングヴエルケ・アクチエンゲゼルシヤフト | 組織蛋白ｐｐ↓１↓８、その取得方法およびその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62116519A (ja) | 1987-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| D'Amore et al. | Angiogenic activity from bovine retina: partial purification and characterization. | |
| JP5887407B2 (ja) | 複合コラーゲンスポンジ及びその製造方法 | |
| DE69111919T2 (de) | Verfahren zur unterdrückung der angiogenese von tumoren. | |
| JPH07501517A (ja) | 局所用フィブリノーゲン複合体 | |
| JPS6028999A (ja) | 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法 | |
| JP2532535B2 (ja) | 組織タンパクｐｐ４含有医薬 | |
| JPH0471894B2 (no) | ||
| CN104721877B (zh) | 一种无菌胶原贴敷料及其制备方法 | |
| JPH06312922A (ja) | 美白剤 | |
| DE4411402A1 (de) | DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen | |
| JPH0571600B2 (no) | ||
| KR100302935B1 (ko) | 사람혈액응고인자xiii과아프로티닌을포함하는약제학적조성물 | |
| JPH0450293B2 (no) | ||
| JPH0730115B2 (ja) | 牛胎盤抽出細胞代謝活性化物質 | |
| Chen et al. | Vascular endothelial cell effectors in fetal calf retina, vitreous, and serum. | |
| JPS6223A (ja) | 組織由来腫瘍増殖阻害物質 | |
| JPH05500809A (ja) | 新規タンパク質及びその製造 | |
| CN117510619B (zh) | 一种创新空间结构的重组ⅲ型人源化胶原蛋白微球及其设计、制备工艺和应用 | |
| JPH0720995B2 (ja) | 牛脾臓由来の細胞増殖促進物質 | |
| JP2824254B2 (ja) | 線維芽細胞増殖物質 | |
| AU676464B2 (en) | Proteolytic mixture containing escharase and method of isolating same | |
| JP2017149710A (ja) | 血管内皮増殖因子産生促進剤の製造方法及び発毛剤の製造方法、並びに血管内皮増殖因子産生促進剤及び発毛剤 | |
| JPS63188699A (ja) | 牛の乳房から抽出せる細胞増殖促進物質及びその抽出法並びにウイルス不活化処理法 | |
| JPS63188698A (ja) | 牛胸腺由来の細胞増殖促進物質 | |
| JPS63188700A (ja) | 牛の血液又は血清から抽出せる細胞増殖促進物質及びその抽出法並びにウイルス不活化処理法 |